Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.42% | |
| Gapped Up | Strength | 0.42% | |
| 20 DMA Resistance | Bearish | -1.23% | |
| Shooting Star Candlestick | Bearish | -1.23% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.23% | |
| Up 3 Days in a Row | Strength | -1.23% | |
| Oversold Stochastic | Weakness | -1.23% | |
| Oversold Stochastic | Weakness | -0.21% | |
| Bullish Engulfing | Bullish | 1.30% | |
| Stochastic Buy Signal | Bullish | 1.30% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 21 minutes ago |
| 10 DMA Resistance | 27 minutes ago |
| 60 Minute Opening Range Breakout | 37 minutes ago |
| Down 3% | about 4 hours ago |
| New 52 Week Low | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.56 |
| 52 Week Low | 23.29 |
| Average Volume | 497,654 |
| 200-Day Moving Average | 28.13 |
| 50-Day Moving Average | 26.65 |
| 20-Day Moving Average | 24.86 |
| 10-Day Moving Average | 24.22 |
| Average True Range | 0.97 |
| RSI (14) | 39.39 |
| ADX | 23.19 |
| +DI | 16.04 |
| -DI | 24.39 |
| Chandelier Exit (Long, 3 ATRs) | 23.71 |
| Chandelier Exit (Short, 3 ATRs) | 26.19 |
| Upper Bollinger Bands | 26.54 |
| Lower Bollinger Band | 23.18 |
| Percent B (%b) | 0.25 |
| BandWidth | 13.52 |
| MACD Line | -0.73 |
| MACD Signal Line | -0.73 |
| MACD Histogram | -0.0026 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.64 | ||||
| Resistance 3 (R3) | 25.76 | 25.35 | 25.37 | ||
| Resistance 2 (R2) | 25.35 | 24.93 | 25.29 | 25.28 | |
| Resistance 1 (R1) | 24.68 | 24.68 | 24.48 | 24.56 | 25.19 |
| Pivot Point | 24.27 | 24.27 | 24.16 | 24.21 | 24.27 |
| Support 1 (S1) | 23.60 | 23.85 | 23.40 | 23.48 | 22.85 |
| Support 2 (S2) | 23.19 | 23.60 | 23.13 | 22.76 | |
| Support 3 (S3) | 22.52 | 23.19 | 22.67 | ||
| Support 4 (S4) | 22.40 |
